Drug profile · INN
thioguanine
LANVIS
thioguanine (LANVIS) is a inosine-5'-monophosphate dehydrogenase (impdh) inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — thioguanine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
thioguanine (LANVIS) is a inosine-5'-monophosphate dehydrogenase (impdh) inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is thioguanine?
thioguanine (LANVIS) is a inosine-5'-monophosphate dehydrogenase (impdh) inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for thioguanine?
LANVIS is a marketed brand name for thioguanine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of thioguanine?
thioguanine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.